Veltrion is building the in-country infrastructure international operators need to enter African markets — regulated counterparty status, attorney-grade legal capability, and direct regulatory access. We are aligning a small group of strategic investors and partners. Detailed materials are shared confidentially with qualified parties on request.
International pharmaceutical, biotech, engineering, and clinical-research operators consistently want access to African markets — and consistently lack a credible local counterparty to execute. Advisory firms give guidance but cannot contract, hold regulated funds, or carry regulatory standing. That gap stalls market entry, deals, and capital deployment.
Veltrion is built to be that counterparty: a regulated, attorney-grade local entity that contracts directly, holds engagement capital in protected trust infrastructure, and navigates SAHPRA and peer regulators across the continent. The same gap exists in every African jurisdiction an operator wants to enter — which is what makes this infrastructure, not a single-market consultancy.
Engagement capital held in a Section 86 attorney trust account, statutorily protected under the Legal Practice Act and the Legal Practitioners' Fidelity Fund — a structural trust advantage advisory firms cannot offer.
SAHPRA Section 22C licensing across wholesaler, distributor, importer, exporter, and Authorised Representative status, targeted operational from Q1 2027 — a regulatory moat that takes years to assemble.
A decade of sponsor-side delivery across global CROs, pharmaceutical sponsors, and multinational vaccine programmes — relationships and credibility that cannot be bought quickly.
Cross-border contracts and regulatory opinions produced under attorney privilege, integrating legal and commercial execution in one counterparty.
One operating model that extends across SAHPRA, NAFDAC, TFDA, PPB, and BoMRA jurisdictions — a repeatable template per market.
Transitioning from founder-led consultancy to a platform — regulatory services, verified talent, and proprietary tooling targeted from 2027.
Milestone-based market-access and regulatory mandates with high-margin senior delivery.
The African Regulatory Desk — recurring monthly revenue with strong retention.
Revenue share with international engineering, equipment, and technology partners on African tenders.
Verified research talent and local staffing without a subsidiary — a scalable, asset-light line.
Section 22C standing enabling wholesaler/distributor/importer activity once operational.
Regulatory pathway acceleration and verified-talent matching — recurring software economics from 2027.
Investors who bring more than capital — sector relationships, regulatory or clinical networks, and a multi-year view of African market infrastructure.
Pharmaceutical, engineering, equipment, and technology principals seeking a regulated local execution partner and a structured route into African markets.
Law firms, CRO networks, and manufacturing partners whose infrastructure complements Veltrion's, on partnership or co-investment terms.
Tell us who you are and what you're looking for. We review every enquiry personally and, where there is fit, share the confidential investor pack under a mutual NDA. This is an expression of interest only and creates no obligation on either side.
This page and any related materials are provided for general information only and are intended for qualified, sophisticated investors and strategic partners. Nothing on this page constitutes, or should be construed as, an offer, invitation, advertisement, or solicitation to subscribe for, purchase, or sell any shares, securities, or financial product, nor an inducement to enter into any investment activity, in any jurisdiction. It is not "advertising" of an offer to the public within the meaning of the Companies Act, 2008, and no prospectus has been registered.
Any potential investment or partnership would be made solely on the basis of definitive confidential documentation and binding agreements, subject to due diligence, applicable law, and the parties' own independent legal, tax, and financial advice. Veltrion makes no representation or warranty as to the achievement of any projection, milestone, or timeline.
Forward-looking statements. References to licensing (including SAHPRA Section 22C), tooling, revenue lines, and timelines are forward-looking, reflect current intentions, and may change. They are not guarantees of future performance or present capability. See our Disclaimers.
Confidential materials are shared only under a mutual non-disclosure agreement and may not be reproduced or distributed. By requesting them, you agree to treat them as confidential.
